MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 106 filers reported holding MARINUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,555 | -23.8% | 4,541 | +2.8% | 0.00% | – |
| Q2 2023 | $47,994 | -21.5% | 4,419 | -50.2% | 0.00% | – |
| Q1 2023 | $61,176 | +6789.2% | 8,866 | +3875.8% | 0.00% | – |
| Q4 2022 | $888 | -99.9% | 223 | -99.9% | 0.00% | – |
| Q3 2022 | $1,668,000 | +37.3% | 250,867 | -0.1% | 0.00% | – |
| Q2 2022 | $1,215,000 | -58.5% | 251,095 | -19.9% | 0.00% | – |
| Q1 2022 | $2,929,000 | -40.0% | 313,282 | -23.8% | 0.00% | – |
| Q4 2021 | $4,885,000 | -9.6% | 411,165 | -13.4% | 0.00% | – |
| Q3 2021 | $5,403,000 | -36.6% | 474,790 | +0.0% | 0.00% | -100.0% |
| Q2 2021 | $8,517,000 | +15.9% | 474,765 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $7,349,000 | +26.9% | 474,765 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $5,792,000 | +35.8% | 474,765 | +43.0% | 0.00% | – |
| Q3 2020 | $4,265,000 | – | 331,908 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |